newsfilter
← Latest News
Business Wire·

Satellos Announces First Participant Dosed in Phase 2 Pediatric Study of SAT-3247 for Duchenne Muscular Dystrophy

BASECAMP, a three-month, randomized, double-blind, placebo-controlled study, will evaluate SAT-3247's safety and tolerability, and effect on muscle force, muscle quality and muscle regeneration Satellos Bioscience